Precision BioSciences (DTIL) News
NASDAQ: DTILHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DTIL news summary
We found 5 recent headlines mentioning Precision BioSciences (DTIL): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, Business Wire. DTIL is making an outsized move today, up 7.09% at $7.40, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Precision BioSciences, Inc. Projects Cash Runway into Fourth Quarter of 2029", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Precision BioSciences headlines
- Precision BioSciences, Inc. Projects Cash Runway into Fourth Quarter of 2029Precision BioSciences, Inc. reported that it expects net proceeds from its previously announced offering, in addition to existing cash and cash equivalents, continued fiscal and operating discipline,…Nasdaq
- Precision BioSciences, Inc. Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsOn November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement with TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters, in…Nasdaq
- Precision BioSciences, Inc. Reports Third Quarter 2026 Financial ResultsPrecision BioSciences, Inc. reported its financial results for the third quarter ended September 30, 2026. Net loss was $7.6 million, or $(0.28) per share (basic and diluted), for the quarter ended…Nasdaq
- Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business UpdateDURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…Business Wire
- Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…Business Wire